Novel anti-cancer agent shows minimal side effects with preliminary evidence of tumor shrinkage

Research results presented at International Conference sponsored jointly by AACR, NCI and EORTC

Washington, DC, November 16, 1999 --- Researchers presented data here today from an ongoing Phase I clinical trial showing that a novel anti-cancer agent, called CCI-779, is well-tolerated and may have antitumor activity. CCI-779 is a derivative of rapamycin, an immunosuppressive agent. Results were presented at the International Conference on Molecular Cancer Therapeutics - Discovery, Development, and Clinical Validation, sponsored by the American Association of Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organization for Research and Treatment of Cancer (EORTC).

"By interfering with key proteins that regulate cell growth, CCI-779 may stop the progression of tumors. This is a unique mechanism of action for an anti-cancer agent," explained Eric Raymond, M.D., senior investigator and associate professor of oncology at the Institut Gustave Roussy in Villejuif, France. "If these preliminary results are confirmed in future observations, this may represent a new and safer treatment for cancer patients."

The results were presented by Jerome Alexandre, a physician-in-training and researcher with Dr. Raymond, who received an AACR Young Investigator Scholar Award, bestowed on predoctoral students, postdoctoral fellows, and physicians-in-training for outstanding abstracts. The study is being conducted in collaboration with Axel Hanauske, M.D., Ph.D. from the Oncology Institute in Munich, Germany, and the sponsor Wyeth-Ayerst Research in Radnor, Pennsylvania /Genetics Institute in Munich, Germany.

Twelve patients received CCI-779 in this ongoing Phase I study. Three patients with renal cell cancer experienced tumor regression after other treatments had failed. At the doses used so far, the main adverse effects were mild skin reactions and inflammation of the mucous membranes, which occurred at all dose levels

Contact: Peter Vigliarolo
Cooney Waters Group, Inc.

Page: 1 2

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
3. Novel approaches to current cellular therapies continue progress toward disease prevention
4. Novel therapies show promise against myeloid leukemia
5. Novel sensors help clear the air
6. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
7. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
8. Novel therapeutic target identified in fight against Rheumatoid Arthritis
9. Novel bacterium detoxifies chlorinated pollutants
10. Novel flu vaccine shows promise in mice
11. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician

Post Your Comments:

(Date:1/21/2019)... ... ... Energetiq Technology, a world leader in high brightness broadband light sources, will ... Photonics West events taking place in San Francisco on February 1 – February 7, ... booth #941 at Photonics West. There will be live demonstrations of Energetiq’s ultra-bright broadband ...
(Date:1/20/2019)... (PRWEB) , ... January 16, 2019 , ... January has ... cooking events company. Not only has the company already hosted several of its ... Fortune 500 companies, Amazon and Janssen Pharmaceuticals, later this month. , Since 2008, ...
(Date:1/14/2019)... ... January 14, 2019 , ... CellMax Life , a ... blood, will present new findings at the ASCO Gastrointestinal Cancer Symposium in San ... results from this study show CellMax Life’s blood test, based on its proprietary ...
Breaking Biology News(10 mins):
(Date:1/30/2019)... ... January 30, 2019 , ... Through ... awarded microbiome research support in study design, planning, sample collection, and analysis to ... Marc D. Cook, PhD, to study the interactions between gut microbial composition and ...
(Date:1/28/2019)... ... January 28, 2019 , ... Fragment-based lead discovery ... In this early stage, false positives can be problematic due to high levels ... that screening techniques are highly sensitive to detect weak interactions. Nanomed , ...
(Date:1/24/2019)... Calif. (PRWEB) , ... January 22, 2019 , ... Dr. ... using the Pall Veterinary Platelet Enhancement Therapy System (V-PET™) for nearly three ... VetStem Regenerative Cell Therapy since 2007 and began using V-PET™ 2016. ...
(Date:1/24/2019)... ... January 23, 2019 , ... Through ... awarded microbiome research support in study design, planning, sample collection, and analysis to ... St. Augustine Campus in Trinidad led by Dr. Elaine Monica Davis, MBBS, MPhil, ...
Breaking Biology Technology:
Cached News: